Sign In

Login

Password

Forgot Password ? Sign Up

Aripiprazole (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Aripiprazole" in French language version.

refsWebsite
Global rank French rank
33nih.gov
4th place
12th place
20doi.org
2nd place
3rd place
4bmscanada.ca
low place
low place
4issn.org
57th place
4th place
2vidal.fr
low place
910th place
2drugs.com
399th place
2,761st place
2wiley.com
222nd place
129th place
2elsevier.com
610th place
265th place
2druglib.com
low place
low place
2europa.eu
68th place
67th place
1theriaque.org
low place
low place
1compendium.ch
low place
low place
1qmul.ac.uk
1,735th place
168th place
1webmd.com
1,169th place
4,112th place
1reuters.com
49th place
87th place
1congresfrancaispsychiatrie.org
low place
low place
1sciencedirect.com
149th place
80th place
1psychopharmacologyinstitute.com
low place
low place
1sudouest.fr
1,740th place
101st place
1rimed.org
low place
low place
1cochrane.org
7,609th place
4,368th place
1biomedcentral.com
2,747th place
1,253rd place
1books.google.com
3rd place
11th place
1bnf.fr
124th place
14th place
1unc.edu
1,538th place
2,720th place
1cambridge.org
305th place
395th place
1aspetjournals.org
6,663rd place
5,973rd place

aspetjournals.org

jpet.aspetjournals.org

  • (en) Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE. et al. « Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist » J Pharmacol Exp Ther. 2005;315(3):1278–87. Consultable sur : http://jpet.aspetjournals.org/content/315/3/1278.full.pdf

biomedcentral.com

bmcpsychiatry.biomedcentral.com

  • Soohyun Joe, Jangho Park, Jongseok Lim, Choongman Park & Joonho Ahn, « Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report », BMC Psychiatry,‎ (lire en ligne)

bmscanada.ca

bnf.fr

catalogue.bnf.fr

  • (en) Laurence Brunton, Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th Edition, China, McGraw-Hill, , 2084 p. (ISBN 978-0-07-162442-8, BNF 42408664), p. 406–410.

books.google.com

  • (en) Peter Haddad, Peter M. Haddad, Serdar Dursun, Bill Deakin, Adverse symptoms and Psychiatric drugs, Oxford medical publications (lire en ligne), p. 207

cambridge.org

journals.cambridge.org

  • (en) Newman-Tancredi A, Heusler P, Martel J-C, Ormière A-M, Leduc N, Cussac D. « Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells » The International Journal of Neuropsychopharmacology 2008;11(03):293–307. Consultable sur http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=1819032

cochrane.org

  • (en) Hirsch LE, Pringsheim T, « Aripiprazole for autism spectrum disorders (ASD) », cochrane.org,‎ (lire en ligne)

compendium.ch

congresfrancaispsychiatrie.org

doi.org

dx.doi.org

  • (en) Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S., « Second-generation antipsychotics for major depressive disorder and dysthymia. », Cochrane Database Syst Rev, vol. 12, no 6,‎ , CD008121. (PMID 21154393, DOI 10.1002/14651858.CD008121.pub2)
  • (en) Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM, « Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. », Prim Care Companion CNS Disord., vol. 11, no 1,‎ , pii: PCC.10m00994. (PMID 21731833, DOI 10.4088/PCC.10m00994gre)
  • Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6,‎ , p. 525–527 (ISSN 0040-5957, PMID 25293487, DOI 10.2515/therapie/2014064, lire en ligne, consulté le )
  • (en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3,‎ , p. 330–340 (ISSN 2051-5545, PMID 30192088, PMCID PMC6127753, DOI 10.1002/wps.20579, lire en ligne, consulté le )
  • Gonidakis F, Ploubidis D, Papadimitriou G, « Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient », Schizophr. Res., vol. 103, nos 1–3,‎ , p. 341–2 (PMID 18262773, DOI 10.1016/j.schres.2008.01.008, lire en ligne)
  • (en) Kranzler, Henry R. et al., « Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol », Alcoholism: Clinical and Experimental Research, vol. 32 issue=4,‎ , p. 573–579 (PMID 18261195, PMCID 3159685, DOI 10.1111/j.1530-0277.2007.00608.x)
  • (en) Konstantin Voronin, Patrick Randall, Hugh Myrick, Raymond Anton, « Aripiprazole Effects on Alcohol Consumption and Subjective Reports in a Clinical Laboratory Paradigm: Possible Influence of Self-Control », Alcoholism: Clinical and Experimental Research, vol. 32, no 11,‎ , p. 1954–1961 (PMID 18782344, PMCID 2588475, DOI 10.1111/j.1530-0277.2008.00783.x)
  • (en) FC Starrenburg et JP Bogers, « How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins », European Psychiatry, Elsevier, vol. 24, no 3,‎ , p. 164–70 (PMID 19285836, DOI 10.1016/j.eurpsy.2009.01.001)
  • (en) Lawler CP. et al., « Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes », Neuropsychopharmacology, vol. 20, no 6,‎ , p. 612–27 (PMID 10327430, DOI 10.1016/S0893-133X(98)00099- 2)
  • (en) Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, « Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist », J Pharmacol Exp Ther, vol. 315, no 3,‎ , p. 1278–87 (PMID 16135699, DOI 10.1124/jpet.105.092155)
  • (en) Jordan, S. et al., « The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor », Eur J Pharmacol, vol. 441, no 3,‎ , p. 137–140 (PMID 12063084, DOI 10.1016/S0014-2999(02)01532-7)
  • (en) Shapiro, DA. et al., « Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology », Neuropsychopharmacology, vol. 28, no 8,‎ , p. 1400–1411 (PMID 12784105, DOI 10.1038/sj.npp.1300203)
  • (en) Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J, « Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms », Biochem Pharmacol, vol. 71, no 4,‎ , p. 521–9 (PMID 16336943, DOI 10.1016/j.bcp.2005.11.007)
  • (en) Kegeles LS. et al., « Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride », Neuropsychopharmacology, vol. 33, no 13,‎ , p. 3111–3125 (PMID 18418366, DOI 10.1038/npp.2008.33)
  • (en) Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF, « Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride », Neuropsychopharmacology, vol. 27, no 2,‎ , p. 248–59 (PMID 12093598, DOI 10.1016/S0893-133X(02)00304-4)
  • (en) « In This Issue », Am J Psychiatry, vol. 165, no 8,‎ , A46 (DOI 10.1176/appi.ajp.2008.165.8.A46)
  • (en) Hedlund PB, « The 5-HT7 receptor and disorders of the nervous system: an overview », Psychopharmacology, vol. 206, no 3,‎ , p. 345–54 (PMID 19649616, PMCID 2841472, DOI 10.1007/s00213-009-1626-0)
  • Sarkisyan G, Roberts AJ, Hedlund PB, « The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior », Behavioural Brain Research, vol. 209, no 1,‎ , p. 99–108 (PMID 20097233, PMCID 2832919, DOI 10.1016/j.bbr.2010.01.022, lire en ligne)
  • (en) Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL, « Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo », Psychopharmacology, vol. 205, no 1,‎ , p. 119–28 (PMID 19337725, PMCID 2821721, DOI 10.1007/s00213-009-1521-8)
  • Andrew J. Cutler, Ronald N. Marcus, Sterling A. Hardy et Amy O'Donnell, « The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia », CNS spectrums, vol. 11, no 9,‎ , p. 691–702; quiz 719 (ISSN 1092-8529, PMID 16946694, DOI 10.1017/s1092852900014784, lire en ligne, consulté le )

druglib.com

drugs.com

elsevier.com

linkinghub.elsevier.com

europa.eu

ema.europa.eu

ec.europa.eu

issn.org

portal.issn.org

  • Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6,‎ , p. 525–527 (ISSN 0040-5957, PMID 25293487, DOI 10.2515/therapie/2014064, lire en ligne, consulté le )
  • (en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3,‎ , p. 330–340 (ISSN 2051-5545, PMID 30192088, PMCID PMC6127753, DOI 10.1002/wps.20579, lire en ligne, consulté le )
  • Andrzej Leś, Katarzyna Badowska-Rosłonek, Marta Łaszcz et Agata Kamieńska-Duda, « Optimization of aripiprazole synthesis », Acta Poloniae Pharmaceutica, vol. 67, no 2,‎ , p. 151–157 (ISSN 0001-6837, PMID 20369792, lire en ligne, consulté le )
  • Andrew J. Cutler, Ronald N. Marcus, Sterling A. Hardy et Amy O'Donnell, « The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia », CNS spectrums, vol. 11, no 9,‎ , p. 691–702; quiz 719 (ISSN 1092-8529, PMID 16946694, DOI 10.1017/s1092852900014784, lire en ligne, consulté le )

nih.gov

ncbi.nlm.nih.gov

  • (en) Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC, « Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes », Cochrane database of systematic reviews (Online), no 3,‎ , p. CD008121 (PMID 23554581)
  • (en) Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S, « Second-generation antipsychotics for major depressive disorder and dysthymia », Cochrane database of systematic reviews (Online), no 12,‎ , p. CD008121 (PMID 21154393)
  • (en) David L. Dunner, Kimberly K. Laubmeier, George Manos, Robert A. Forbes, Ross A. Baker et Robert M. Berman, « Beneficial Effects of Adjunctive Aripiprazole in Major Depressive Disorder Are Not Dependent on Antidepressant Therapy History: A Post Hoc Analysis of 3 Randomized, Double-Blind, Placebo-Controlled Trials », Prim Care Companion CNS Disord, vol. 14, no 6,‎ , p. CD008121 (PMID 3622536)
  • (en) Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A, « The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. », Prim Care Companion CNS Disord, vol. 68, no 6,‎ , p. 843-53 (PMID 17592907)
  • (en) Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S., « Second-generation antipsychotics for major depressive disorder and dysthymia. », Cochrane Database Syst Rev, vol. 12, no 6,‎ , CD008121. (PMID 21154393, DOI 10.1002/14651858.CD008121.pub2)
  • (en) Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, Carson W, Baker RA, Marcus RN., « Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. », Neuropsychiatr Dis Treat., no 7),‎ , p. 303-12 (PMID 21655344)
  • (en) Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM, « Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. », J Clin Psychopharmacol, vol. 29, no 4,‎ , p. 362-7 (PMID 19593176)
  • (en) Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, Pikalov A, Qi Y, Carlson BX, Marcus RN, Berman RM., « Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163) », Prim Care Companion J Clin Psychiatry, vol. 11, no 6,‎ , p. 344-52 (PMID 20098527)
  • (en) Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM, « Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. », Prim Care Companion CNS Disord., vol. 11, no 1,‎ , pii: PCC.10m00994. (PMID 21731833, DOI 10.4088/PCC.10m00994gre)
  • Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6,‎ , p. 525–527 (ISSN 0040-5957, PMID 25293487, DOI 10.2515/therapie/2014064, lire en ligne, consulté le )
  • (en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3,‎ , p. 330–340 (ISSN 2051-5545, PMID 30192088, PMCID PMC6127753, DOI 10.1002/wps.20579, lire en ligne, consulté le )
  • Gonidakis F, Ploubidis D, Papadimitriou G, « Aripiprazole-induced rabbit syndrome in a drug-naive schizophrenic patient », Schizophr. Res., vol. 103, nos 1–3,‎ , p. 341–2 (PMID 18262773, DOI 10.1016/j.schres.2008.01.008, lire en ligne)
  • Andrzej Leś, Katarzyna Badowska-Rosłonek, Marta Łaszcz et Agata Kamieńska-Duda, « Optimization of aripiprazole synthesis », Acta Poloniae Pharmaceutica, vol. 67, no 2,‎ , p. 151–157 (ISSN 0001-6837, PMID 20369792, lire en ligne, consulté le )
  • (en) Kranzler, Henry R. et al., « Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol », Alcoholism: Clinical and Experimental Research, vol. 32 issue=4,‎ , p. 573–579 (PMID 18261195, PMCID 3159685, DOI 10.1111/j.1530-0277.2007.00608.x)
  • (en) Konstantin Voronin, Patrick Randall, Hugh Myrick, Raymond Anton, « Aripiprazole Effects on Alcohol Consumption and Subjective Reports in a Clinical Laboratory Paradigm: Possible Influence of Self-Control », Alcoholism: Clinical and Experimental Research, vol. 32, no 11,‎ , p. 1954–1961 (PMID 18782344, PMCID 2588475, DOI 10.1111/j.1530-0277.2008.00783.x)
  • (en) FC Starrenburg et JP Bogers, « How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins », European Psychiatry, Elsevier, vol. 24, no 3,‎ , p. 164–70 (PMID 19285836, DOI 10.1016/j.eurpsy.2009.01.001)
  • (en) Nguyen CT, Rosen JA, Bota RG. « Aripiprazole Partial Agonism at 5-HT2C: A Comparison of Weight Gain Associated With Aripiprazole Adjunctive to Antidepressants With High Versus Low Serotonergic Activities » Prim Care Companion CNS Disord. [Internet]. 2012;14(5). Consultable sur : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583771/
  • (en) Lawler CP. et al., « Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes », Neuropsychopharmacology, vol. 20, no 6,‎ , p. 612–27 (PMID 10327430, DOI 10.1016/S0893-133X(98)00099- 2)
  • (en) Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, « Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist », J Pharmacol Exp Ther, vol. 315, no 3,‎ , p. 1278–87 (PMID 16135699, DOI 10.1124/jpet.105.092155)
  • (en) Jordan, S. et al., « The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor », Eur J Pharmacol, vol. 441, no 3,‎ , p. 137–140 (PMID 12063084, DOI 10.1016/S0014-2999(02)01532-7)
  • (en) Shapiro, DA. et al., « Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology », Neuropsychopharmacology, vol. 28, no 8,‎ , p. 1400–1411 (PMID 12784105, DOI 10.1038/sj.npp.1300203)
  • (en) Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J, « Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms », Biochem Pharmacol, vol. 71, no 4,‎ , p. 521–9 (PMID 16336943, DOI 10.1016/j.bcp.2005.11.007)
  • (en) Kegeles LS. et al., « Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride », Neuropsychopharmacology, vol. 33, no 13,‎ , p. 3111–3125 (PMID 18418366, DOI 10.1038/npp.2008.33)
  • (en) Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF, « Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride », Neuropsychopharmacology, vol. 27, no 2,‎ , p. 248–59 (PMID 12093598, DOI 10.1016/S0893-133X(02)00304-4)
  • (en) Hedlund PB, « The 5-HT7 receptor and disorders of the nervous system: an overview », Psychopharmacology, vol. 206, no 3,‎ , p. 345–54 (PMID 19649616, PMCID 2841472, DOI 10.1007/s00213-009-1626-0)
  • Sarkisyan G, Roberts AJ, Hedlund PB, « The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior », Behavioural Brain Research, vol. 209, no 1,‎ , p. 99–108 (PMID 20097233, PMCID 2832919, DOI 10.1016/j.bbr.2010.01.022, lire en ligne)
  • (en) Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL, « Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo », Psychopharmacology, vol. 205, no 1,‎ , p. 119–28 (PMID 19337725, PMCID 2821721, DOI 10.1007/s00213-009-1521-8)
  • Andrew J. Cutler, Ronald N. Marcus, Sterling A. Hardy et Amy O'Donnell, « The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia », CNS spectrums, vol. 11, no 9,‎ , p. 691–702; quiz 719 (ISSN 1092-8529, PMID 16946694, DOI 10.1017/s1092852900014784, lire en ligne, consulté le )

pubmed.ncbi.nlm.nih.gov

druginfo.nlm.nih.gov

  • (en) Drug information portal, [2]

psychopharmacologyinstitute.com

qmul.ac.uk

chem.qmul.ac.uk

reuters.com

rimed.org

  • (en) Noah S. Philip, MD, « An Aripiprazole Discontinuation Syndrome », RIMED.ORG,‎ (lire en ligne)

sciencedirect.com

sudouest.fr

theriaque.org

unc.edu

pdsp.med.unc.edu

  • (en) « PDSP Ki Database », National Institute of Mental Health (consulté le )

vidal.fr

webmd.com

wiley.com

onlinelibrary.wiley.com